PDL BioPharma, Inc.
932 Southwood Blvd.
Incline Village
NV
89451
United States
Tel: 775-832-8500
Website: http://www.pdl.com/
435 articles about PDL BioPharma, Inc.
-
PDL BioPharma Reports 2020 First Quarter Financial Results
5/7/2020
PDL BioPharma, Inc. reports financial results for the three months ended March 31, 2020 and provides a business update
-
PDL BioPharma to Participate in Jefferies 2019 Global Healthcare Conference
5/28/2019
PDL BioPharma, Inc. announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at the Jefferies 2019 Global Healthcare Conference in New York City.
-
PDL BioPharma to Participate at UBS Global Healthcare Conference
5/15/2019
PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at the UBS Global Healthcare Conference in New York City.
-
PDL BioPharma Reports 2019 First Quarter Financial Results
5/9/2019
PDL BioPharma, Inc. reports financial results for the three months ended March 31, 2019
-
PDL BioPharma to Announce First Quarter 2019 Financial Results on May 9, 2019
5/2/2019
PDL BioPharma, Inc. announced that it will release its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after market close.
-
PDL BioPharma to Hold Annual Meeting of Stockholders on June 20, 2019
4/16/2019
PDL BioPharma, Inc. announced that the Company will hold its annual meeting of stockholders on Thursday, June 20, 2019, at 3:00 p.m. Pacific Time for all stockholders of record on April 26, 2019.
-
PDL BioPharma Announces Equity Investment in Evofem Biosciences
4/11/2019
Transaction supports strategy of investing in near-commercial stage products with potential to create significant shareholder value Provides Evofem capital to prepare for the successful launch of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand female contraceptive
-
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
4/11/2019
Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), today announced it has entered into a securities purchase agreement pursuant to which Evofem can raise up to $80 million through a private placement of common stock from new and existing investors, including a strategic investment from PDL BioPharma, Inc.
-
PDL BioPharma to Participate at H.C. Wainwright & Co. Global Life Sciences Conference
3/26/2019
The session will be webcast live and will occur on Tuesday, April 9, 2019, at 10:50 a.m. British Standard Time.
-
PDL BioPharma Reports 2018 Fourth Quarter and Full Year Financial Results
3/14/2019
PDL BioPharma, Inc. reports financial results for the three and 12 months ended December 31, 2018
-
PDL BioPharma to Participate at 31st Annual Roth Conference
3/12/2019
PDL BioPharma, Inc. announces that Peter Garcia, PDL's vice president and chief financial officer, will participate in a series of investor meetings at the 31st Annual Roth Conference being held March 17-19 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
-
PDL BioPharma to Announce 2018 Fourth Quarter and Full Year Financial Results on March 14, 2019
3/7/2019
PDL BioPharma, Inc. announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018, on Thursday, March 14, 2019, after market close.
-
PDL BioPharma to Participate at Cowen 39th Annual Health Care Conference
3/5/2019
PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at the Cowen 39th Annual Health Care Conference in New York City.
-
PDL BioPharma Announces Launch of an Authorized Generic of Tekturna® (aliskiren) in Partnership with Prasco Laboratories
3/4/2019
PDL BioPharma, Inc. announces the U.S. commercial launch of an authorized generic of Tekturna®, aliskiren hemifumarate 150 mg and 300 mg tablets.
-
PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
11/19/2018
The session will be webcast live and will occur on Tuesday, November 27, 2018, at 1:50 p.m. EST.
-
PDL BioPharma Reports Third Quarter 2018 Financial Results
11/6/2018
Announces CEO succession plan
-
PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018
10/31/2018
PDL BioPharma, Inc. today announced that it will release its third quarter financial results for the period ended September 30, 2018, on Tuesday, November 6, 2018, after market close.
-
PDL BioPharma Names Edward Imbrogno Vice President of Finance
10/8/2018
Mr. Imbrogno brings to PDL more than 30 years of public accounting and financial reporting experience and will report to Vice President and Chief Financial Officer, Peter Garcia.
-
PDL BioPharma Announces New $100 Million Stock Repurchase Program
9/24/2018
Purchases may be made in open-market transactions, in block transactions on or off an exchange,
-
SevenSaoi Capital Delivers Letter to the Board of PDL BioPharma
9/20/2018
Expresses Serious Concerns Regarding PDL's Misguided Acquisition Strategy, Which Has Destroyed Shareholder Value